IL2 and diabetes mellitus: The inability of the expanded Treg cells to home in the damaged tissue might also lie behind the failure of an IL-2-based therapy for diabetes (Long et al, 2013); indeed, supplementation with IL-2 further augmented the proliferative effects of rhIGF-1 on Tregs in vitro.